September 15th, 2015 · Leave a Comment
JACKSONVILLE, Fla. â€” Researchers on Mayo Clinicâ€™s Florida campus have been awarded a $13.3 million, five-year federal grant to test a vaccine designed to prevent the recurrence of triple-negative breast cancer, a subset of breast cancer for which there are no targeted therapies.
The clinical trial, which will enroll 280 patients at multiple clinical sites, is expected to begin early in 2016.
The grant, the Breakthrough Award from the U.S. Department of Defenseâ€™s Breast Cancer Research Program, will fund a national, phase II clinical trial testing the ability of a folate receptor alpha vaccine to prevent recurrence of this aggressive cancer following initial treatment.
Journalists: Sound bites with Dr. Knutson are available in the downloads.
Tags: Breast Cancer, Dr Edith Perez, Dr Keith Knutson, Florida News Release, immunology, Mayo Clinic Cancer Center, Mayo Clinicâ€™s Florida campus, Mayo Clinicâ€™s Rochester, Medical Research, Minnesota campus, News Release, Cancer
September 11th, 2015 · Leave a Comment
JACKSONVILLE, Fla. â€” Mayo Clinicâ€™s Florida campusÂ was the nationâ€™s second largest recruiting site, and largest in the Southeast, to participate in a landmark study that has found maintaining systolic blood pressure at a target of 120 greatly reduced the risk of cardiovascular complications and death in older adults with high blood pressure.
â€śItâ€™s been widely assumed that if youâ€™re older, itâ€™s OK to have a higher blood pressure, and this study challenges that notion,â€ť said William E. Haley, M.D., principal investigator for Mayo Clinic of the SPRINT study and a nephrologist at Mayo Clinicâ€™s Florida campus.
The National Institutes of Health today announced the Systolic Blood Pressure Intervention Trial (SPRINT) found management of high blood pressure with a target of 120, rather than the commonly recommended 140, reduced risk of cardiovascular disease by nearly one third, and reduced risk of death by nearly 25 percent, in a group of adults 50 years and older with high blood pressure.
â€śThis is truly a landmark trial because it deals with a common and deadly condition, and it includes patients over age 75,and those who have existing cardiovascular and kidney disease,â€ť Dr. Haley said. â€śThese groups have typically been excluded from most trials. This trial is going to inform treatment for those groups, which happen to be the same groups who have the most complications.â€ť
Hypertension is the most common medical condition in United States, affecting one in three Americans, and about 1 billion people worldwide.
Journalists: Sound bites with Dr. Haley are available in the downloads.
MEDIA CONTACT: Kevin Punsky,Â Mayo Clinic Public Affairs, 507-284-5005, email@example.com
September 8th, 2015 · Leave a Comment
Journalists: Sound bites with gastroenterologistÂ Michelle Lewis, M.D., are available in the downloads.
JACKSONVILLE, Fla. and ROCHESTER, Minn. â€” Mayo Clinicâ€™s Florida and Rochester, Minnesota campuses have been named National Pancreas Foundation Centers by the non-profit patient-centered National Pancreas Foundation. The foundation describes these centers as â€śpremier healthcare facilities that focus on multidisciplinary treatment of pancreatitis, treating the whole patient with a focus on the best possible outcomes and an improved quality of life.â€ť
Because treatment of pancreatitis and other pancreatic disorders is often inconsistent, the foundation says, it created the designation to distinguish institutions that focus on patient-centered care either for treating the disease or to get an expert second opinion.
The foundation designated 30 institutions in the United States as centers.
September 1st, 2015 · Leave a Comment
JACKSONVILLE, Fla. â€“ Mayo Clinic and the University of North FloridaÂ (UNF)Â are honoring National Breast Cancer Awareness Month in October by hosting the 11th annual â€śUpbeat Pink: A Musical Tribute to Breast Cancer Survivorshipâ€ť concert on Friday, Oct. 9 at 7:30 p.m. in Lazzara Performance Hall, UNF Fine Arts Building on the universityâ€™s campus in Jacksonville. The Upbeat Pink concert is free and open to the public.
Guest speakers will include Stephanie Hines, M.D. from Mayo Clinicâ€™s Florida campus and Patricia Dunbar-Norris, a breast cancer survivor.
August 24th, 2015 · Leave a Comment
JACKSONVILLE, Fla. â€” Cancer researchers dream of the day they can force tumor cells to morph back to the normal cells they once were. Now, researchers on Mayo Clinicâ€™s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
The finding, published in Nature Cell Biology, represents â€śan unexpected new biology that provides the code, the software for turning off cancer,â€ť says the studyâ€™s senior investigator, Panos Anastasiadis, Ph.D., chair of the Department of Cancer Biology on Mayo Clinicâ€™s Florida campus.
Journalists: Sound bites with Dr. Anastasiadis are available in the downloads.
July 23rd, 2015 · Leave a Comment
JACKSONVILLE, Fla. â€” In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinicâ€™s Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.
In testing multiple HDAC inhibitors in combination with the chemotherapy drug paclitaxel, known to give some benefit for this aggressive cancer, they found that class II HDAC inhibitors signal through a newly discovered pathway to promote synergy with chemotherapy treatment.
Journalists: Sound bites with Dr. Copland are available in the downloads.
July 21st, 2015 · Leave a Comment
JACKSONVILLE, Fla. â€” U.S. News & World Report again has named Mayo Clinicâ€™s Florida campus to its annual list of â€śAmericaâ€™s Best Hospitalsâ€ť published online today. Mayo Clinic is ranked No. 1 in the Jacksonville metro area, No. 4 in Florida and among the top 50 hospitals nationally in cancer, gastroenterology (GI) and GI surgery, geriatrics, and neurology and neurosurgery.
â€śThis honor reflects the deep commitment of our staff to provide the highest quality of care to our patients every day,â€ť says Gianrico Farrugia, M.D., CEO of Mayo Clinicâ€™s Florida campus. â€śOur employees are critical to the success of Mayo Clinic. Iâ€™m extremely grateful for their dedication and commitment to making the patient experience the very best it can be.â€ť
Journalists: Sound bites from Dr. Farrugia are available in the downloads.
July 20th, 2015 · Leave a Comment
JACKSONVILLE, Fla. â€” Researchers on Mayo Clinicâ€™s Florida campus have identified key differences between patients with sporadic amyotrophic lateral sclerosis (ALS or Lou Gehrigâ€™s disease) and those with the most common genetic form of ALS, a mutation in the C9orf72 gene.
Their findings, reported online today in Nature Neuroscience, demonstrate that ALS patients show abnormalities in levels and processing of ribonucleic acids (RNA), biological molecules that determine what gene information is used to guide protein synthesis.
More than 30,000 Americans live with ALS, a condition that destroys motor neuron cells that control essential muscle activity, such as speaking, walking, breathing and swallowing. While increasing efforts are geared toward therapeutic development, an effective drug for ALS has yet to be identified, in large part because of our incomplete understanding of the disease.
â€śOur results using advanced, modern laboratory techniques called next-generation sequencing, allowed us to acquire a library of new knowledge about patients with ALS,â€ť says the studyâ€™s senior author, Leonard Petrucelli, Ph.D., chair of the Department of Neuroscience on Mayo Clinicâ€™s Florida campus.
Dr. Petrucelli and Hu Li, Ph.D., assistant professor of pharmacology on Mayo Clinicâ€™s campus in Rochester, Minn., led a team of investigators who carefully analyzed the RNA from human brain tissues. They found that ALS brains had numerous RNA defects, compared to nondisease brains. They also predicted molecular events that may be altered due to the changes found in RNAs involved in pathways regulating those events and that may contribute to ALS.
June 29th, 2015 · Leave a Comment
JACKSONVILLE, Fla. â€” Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical trials, believe they know why dasatinib failed â€” and what to do about it.
In the online issue of Molecular Oncology, investigators report finding that dasatinib inhibits proteins that promote cancer growth as expected but also suppresses proteins that protect against cancer.
The findings suggest that pretesting patient glioblastoma biopsies will help identify who may respond well to dasatinib and who should avoid using the drug, says the studyâ€™s senior author, Panos Z. Anastasiadis, Ph.D., chair of the Department of Cancer Biology at Mayo Clinic in Florida.
June 17th, 2015 · Leave a Comment
JACKSONVILLE, Fla. â€” Mayo Clinic in Florida has been named a Pulmonary Hypertension Care Center by the Pulmonary Hypertension Association. The designation is given to centers that provide early diagnosis of pulmonary hypertension, a full range of therapies and specialized care, outcomes follow-up and clinical research and studies, among other points of excellence.
Mayo Clinic in Florida is the only Pulmonary Hypertension Care Center in the Southeast and one of only 26 in the country.